National Institute on Drug Abuse; Notice of Closed Meetings, 2710 [2025-00455]
Download as PDF
<![CDATA[
2710
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
National Institutes of Health
Dated: January 6, 2025.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute on Drug Abuse;
Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Studies to Investigate the
Interrelationship Between Sleep and/or
Circadian Rhythms and Substance Use
Disorders.
Date: February 21, 2025.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Interplay of Autophagy Regulated Cell Death
and HIV Pathogenesis in Substance Use
Disorders and Research on the NeuroImmune Axis in the Context of HIV and
Substance Use.
Date: February 24, 2025.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 402–
6965, meysam.yazdankhah@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
VerDate Sep<11>2014
18:48 Jan 09, 2025
Jkt 265001
[FR Doc. 2025–00455 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Human Genome Research.
This is a video assisted meeting held
virtually. It is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations, should notify the
contact person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from
https://www.genome.gov/eventcalendar/105th-Meeting-of-NationalAdvisory-Council-for-Human-GenomeResearch.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Human Genome Research.
Date: February 10–11, 2025.
Closed: February 10, 2025, 9:00 a.m. to
10:00 a.m.
Agenda: To review and evaluate grant
applications.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Open: February 10, 2025, 10:00 a.m. to 6:00
p.m.
Agenda: Report of Institute Director and
Institute Staff.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Closed: February 11, 2025, 11:00 a.m. to
5:00 p.m.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Contact Person: Jennifer L. Troyer, Ph.D.,
Director, Division of Extramural Operations,
National Human Genome Research Institute,
National Institutes of Health, 5635 Fishers
Lane, Suite 4076, Rockville, MD 20852, (301)
480–3565, troyerj@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.genome.gov/council, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: January 6, 2025.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2025–00469 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS–
2023–1 Phase II: Adaptation of CRISPR-Based
In Vitro Diagnostics for Rapid Detection of
Select Eukaryotic Pathogens (Topic 119).
Date: February 4, 2025.
Time: 1:00 p.m. to 4:00 p.m.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Video Assisted Meeting).
Agenda: To review and evaluate contract
proposals.
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Page 2710]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00455]
[[Page 2710]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanistic Studies to Investigate the
Interrelationship Between Sleep and/or Circadian Rhythms and
Substance Use Disorders.
Date: February 21, 2025.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 827-4471,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Interplay of Autophagy Regulated Cell Death and HIV
Pathogenesis in Substance Use Disorders and Research on the Neuro-
Immune Axis in the Context of HIV and Substance Use.
Date: February 24, 2025.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Meysam Yazdankhah, Ph.D., Scientific Review
Officer, Scientific Review Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,
(301) 402-6965, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 6, 2025.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2025-00455 Filed 1-10-25; 8:45 am]
BILLING CODE 4140-01-P
